Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have received an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $50.0833.

Several equities research analysts have weighed in on PHVS shares. Wolfe Research initiated coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price for the company. Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Citizens Jmp lowered their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, Morgan Stanley raised their target price on shares of Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research report on Thursday, June 25th.

Insider Transactions at Pharvaris

In related news, Director Viviane Monges sold 9,667 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $30.29, for a total value of $292,813.43. Following the completion of the transaction, the director owned 5,500 shares of the company’s stock, valued at $166,595. The trade was a 63.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Berndt Modig sold 2,291 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $31.07, for a total transaction of $71,181.37. Following the completion of the transaction, the chief executive officer directly owned 135,209 shares of the company’s stock, valued at $4,200,943.63. This trade represents a 1.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 303,356 shares of company stock worth $9,746,065. Insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PHVS. Tudor Investment Corp ET AL bought a new position in Pharvaris in the third quarter worth about $1,943,000. PSP Research LLC bought a new stake in shares of Pharvaris in the 4th quarter valued at about $569,000. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 710.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock valued at $676,000 after buying an additional 23,743 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Pharvaris in the 4th quarter worth approximately $1,536,000. Finally, Eversept Partners LP purchased a new position in shares of Pharvaris in the 4th quarter worth approximately $12,187,000.

Pharvaris Stock Performance

Shares of NASDAQ PHVS opened at $35.16 on Thursday. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -11.06 and a beta of -2.34. The stock has a 50 day moving average price of $31.98 and a 200 day moving average price of $28.89. Pharvaris has a 52-week low of $19.12 and a 52-week high of $36.60.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. Analysts forecast that Pharvaris will post -3.2 earnings per share for the current year.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.